Long-term protection study for bivalent HPV vaccine
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study follows up with people who received the bivalent HPV vaccine to see how long their protection lasts and whether any breakthrough infections occur. It involves extra blood tests or follow-up visits over several years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the earlier HPV vaccine study (311-HPV-1005) at the Mianyang Center.
- You got at least one dose of the bivalent HPV vaccine during that study.
- For the blood test part: you completed all three vaccine doses and had valid antibody blood tests before the first dose and one month after the third dose.
- For the infection follow-up part: you are at least 18 years old (or will turn 18 during this study).
- You can give informed consent (or your parent/guardian can if you are under 18).
- You agree to either blood draws at specific time points (Months 42 and 66) or remote/site follow-up visits to report HPV-related information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
This study tests a new HPV vaccine in Chinese women. It looks at whether the vaccine is safe and effective for women who have already had a different HPV vaccine (the bivalent one) and for women who have never had any HPV vaccine.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This early study tests a new HPV (human papillomavirus) vaccine to see if it can safely trigger an immune response in healthy adults. It’s for people who have not had an HPV vaccine before and can follow study vaccination and pregnancy-prevention rules.
This trial tests whether a vaccine against HPV can help prevent pre-cancerous lesions from coming back after you've had them. It's for people who have had high-grade pre-cancerous lesions but haven't yet been treated for them.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
Hear when a new Human Papillomavirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.